Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis-Reference-Cited by-同舟云学术

Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis

Published:2017-12-05 Issue:4 Volume:24 Page:462-467
ISSN:1075-122X
Container-title:The Breast Journal
language:en
Short-container-title:Breast J

Author:

Bayo Juan¹^ORCID,Aviñó Victoria¹,Toscano Fátima¹,Jiménez Francisco¹

Affiliation:

1. Department of Medical Oncology; Complejo Hospitalario de Huelva; Huelva Spain

Publisher

Hindawi Limited

Subject

Oncology,Surgery,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/tbj.12927/fullpdf

Reference25 articles.

1. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

2. Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer;Chen;Oncol Lett,2015

3. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial;Coudert;J Clin Oncol,2007

5. National Comprehensive Cancer Network Practice Guidelines in Oncology v.2.2010. Myeloid Growth Factors 2016 https://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cetylpyridinium chloride inhibits human breast tumor cells growth in a no-selective way;Journal of Applied Biomaterials & Functional Materials;2022-01

2. Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer;Breast Cancer Research and Treatment;2021-09-17

3. Heterotargeted Nanococktail with Traceless Linkers for Eradicating Cancer;Advanced Functional Materials;2019-09-16

4. Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer;Cancer Management and Research;2019-01